12
Apr

Investigators for Intercept Pharmaceuticals spelled out the impact of its lead therapy on rare cases of a liver disease called primary biliary cirrhosis (PBC), fleshing out the results of a late-stage study that it will use to seek U.S. and European approvals later in the year.

…read more

Source: Intercept grabs the spotlight at EASL, builds case for lead drug OCA

    

0 No comments